A BioPharma Solutions Company

We are a pioneering Biopharma-Technology enterprise committed to enhancing human well-being and enriching quality of life by expediting drug discovery and development. Our objective is to harness state of the art technologies to identify and execute on the best drug discovery solutions to solve unmet needs of patients across rare and common disease areas. We are drug hunters and disease detectives working with the healthcare industry stakeholders at large to develop and implement solutions to end patient suffering.

Powering Pharma to Craft AI Solutions with RxAgentAI

We harness state of the art technology encompassing drug technologies, precision medicine, artificial intelligence, machine learning and real-world medicine to craft custom solutions. We leverage cutting edge research and technology tools such as RxAgentAI applying Artificial Intelligence and Machine Learning for drug discovery and development. Embracing the transformative potential of Generative AI, VedTechBio sits at the cutting edge of pharmaceutical innovation. Our commitment to intelligent innovation emphasizes that VedTechBio is not just participating in the journey from bench to bedside—we're leading the way.

Differentiated Capabilities, and Experienced Resource Pool

Our proficiency in biology, chemistry and clinical development and deep experience applying AI and ML to solve complex problems provide end to end solutions to transform drug discovery and development. Our leadership brings long experience of solving challenges and delivering successful solutions across the pharma value chain. Unique resource pool with medical, scientific and technology backgrounds complements each other in applying cutting edge technological solutions for novel target discovery and drug development.

Established Track-record of Successful Solutions for our Partners

We have been successfully pioneering solutions to pharma across the drug discovery and development value chain. We have accelerated the pace of drug discovery by identifying targets and prioritizing most relevant indications currently in the advanced stage of development. We have defined several protein targets, identified hit compounds from large libraries and designed it for synthesis reaching to POC stage. Our translational research team is leading the way to design animal models and experiments to validate compounds and product concepts for repurposing in different indications.